Brainstorm Cell Therapeutics (NSDQ:BCLI) said today that it inked an agreement with the University of California Irvine Medical Center to enroll patients in the Phase III trial of its NurOwn mesenchymal stem cell-based platform for amyotrophic lateral sclerosis.
This marks the third medical center to work with Brainstorm to enroll patients in the late-stage pivotal trial. The company said last week that Massachusetts General Hospital and California Pacific Medical Center both agreed to participate in the trial.
“We are privileged to have UCI and Dr. Goyal join our pivotal Phase III study of NurOwn,” Brainstorm’s chief executive & president Chaim Lebovits said in prepared remarks. “Adding UCI as an enrolling center with Dr. Goyal as principal investigator will make the treatment more accessible to patients in California, and we welcome the opportunity to work with this prestigious institution.”
“NurOwn is a very promising treatment with compelling Phase II data in patients with ALS; we look forward to further advancing it in clinical development and confirming the therapeutic benefit with Brainstorm,” Dr. Namita Goyal, director of the ALS Clinic in the Neuromuscular Medicine Fellowship and Neuromuscular Diagnostic Laboratory at UCI, added.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.